| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/18/2009 | CN100462359C 5-sulfanyl-4H-1,2,4-triazole derivatives and their use as a medicament |
| 02/18/2009 | CN100462354C Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| 02/18/2009 | CN100462352C Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/18/2009 | CN100462095C Brain and intellectual health care medicine and its preparation |
| 02/18/2009 | CN100462080C Enteral composition for the prevention and/or treatment of sepsis |
| 02/18/2009 | CN100462073C Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 02/18/2009 | CN100462072C Medicine composition used for injection and its preparing method |
| 02/17/2009 | US7491825 e.g. N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl -quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate; antiinflammatory agent; asthma, chronic bronchitis, allergic rhinitis, obstructive pulmonary disease (COPD) |
| 02/17/2009 | US7491803 Atopic dermatitis, airway inflammation, airway hyperresponsiveness, or asthma; cytokine biosynthesis inhibition; diagnostic kits |
| 02/17/2009 | US7491801 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 02/17/2009 | US7491746 Treating cell proliferation disorder, anticancer agents |
| 02/17/2009 | US7491745 e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide; |
| 02/17/2009 | US7491740 Isoxazoline compounds having MIF antagonist activity |
| 02/17/2009 | US7491739 TNF-α production inhibitors |
| 02/17/2009 | US7491734 psychotic and intellectual impairment disorders; Alzheimer's disease, cognitive or attention disorders, antidepressant, anxiolytic agent; ,smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease |
| 02/17/2009 | US7491730 Compositions useful as inhibitors of GSK-3 |
| 02/17/2009 | US7491716 Glycogen synthase kinase-3 inhibitors such as [1-(4-Imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-6,7-dihydro-6H-[1,4]diazepino[6,7,1-hi]indol-6-yl]-[morpholin-4-yl]methylenecyanamide, used for treating diabetes, Alzheimer's disease and for stimulating bone deposition in mammals |
| 02/17/2009 | US7491411 dialysis or replacement fluid separated into two or more component solutions intended for admixture to use, provides the final dialysis or replacement fluid; aqueous NaHCO3 in one compartment, dissolved CO2 in separate compartment containing HCl or lactic or CH3COOH, NaCl, MgCl2, KCl, CaCl2, glucose |
| 02/17/2009 | US7491410 Food grade transglutaminase inhibitor and uses thereof |
| 02/17/2009 | US7491047 Delivery of antihistamines through an inhalation route |
| 02/17/2009 | CA2445189C Carboline derivatives as pdev inhibitors |
| 02/17/2009 | CA2428315C Indole and dihydroindole derivatives |
| 02/17/2009 | CA2400217C Pteridine compounds for the treatment of psoriasis |
| 02/17/2009 | CA2383785C Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 02/17/2009 | CA2383555C 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/17/2009 | CA2356087C Methods and compositions for treatment of cell proliferative disorders |
| 02/17/2009 | CA2347856C Dry powder for inhalation |
| 02/17/2009 | CA2334267C Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| 02/12/2009 | WO2009020270A1 Delivery system for nucleic acids using cationic polymer conjugates |
| 02/12/2009 | WO2009020192A1 Composition for oral intake for preventing ultraviolet damage |
| 02/12/2009 | WO2009020140A1 Adamantylurea derivative |
| 02/12/2009 | WO2009020119A1 Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| 02/12/2009 | WO2009020058A1 Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion |
| 02/12/2009 | WO2009019815A1 Novel γ-secretase inhibitor |
| 02/12/2009 | WO2009019478A1 Treatments and prevention of hydrocephalus |
| 02/12/2009 | WO2009019463A1 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue |
| 02/12/2009 | WO2009019202A1 N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases |
| 02/12/2009 | WO2008153813A3 Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof |
| 02/12/2009 | WO2008057933A3 Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
| 02/12/2009 | US20090044299 Artichoke hybrid named 'PS-H2015' |
| 02/12/2009 | US20090043379 Drug delivery systems for the prevention and treatment of vascular diseases |
| 02/12/2009 | US20090042985 Process for the Preparation of Fatty Acids |
| 02/12/2009 | US20090042984 Cool-Pet System |
| 02/12/2009 | US20090042981 FDA Orange book listed patent for fesoterodine fumarate; urinary incontinence; isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester is fesoteridine |
| 02/12/2009 | US20090042972 Methods of using low-dose doxepin for the improvement of sleep |
| 02/12/2009 | US20090042971 Method of using low-dose doxepin for the improvement of sleep |
| 02/12/2009 | US20090042961 Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| 02/12/2009 | US20090042953 IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES |
| 02/12/2009 | US20090042911 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-YL](3R,5S)-3, 5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 |
| 02/12/2009 | US20090042905 Triazole derivatives as ligands of g-protein coupled receptors |
| 02/12/2009 | US20090042885 2-(2-((2R)-2-heptylaminomethyl-5-oxopyrrolidin-1-yl)ethylthio)-1,3-thiazole-4-carboxylic acid; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder |
| 02/12/2009 | US20090042877 such as ethyl 6-oxo-7-phenyl-3-(pyridin-3-ylamino)-6,7-dihydrothieno [2,3-b]pyridine-2-carboxylate, potent and selective inhibitors of p38 MAP kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders |
| 02/12/2009 | US20090042850 Compositions and methods for cytoprotection |
| 02/12/2009 | US20090042829 Nucleic Acid-Lipopolymer Compositions |
| 02/12/2009 | US20090042825 Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| 02/12/2009 | US20090042807 By reducing macrophage NO production through administration of one or more enzyme inhibitors, selected from tripeptides, tetrapeptides and pentapeptides; inhibition of neucrosis factor kappa Beta mediated inflammatory cytokine release |
| 02/12/2009 | US20090042797 Gamma-heregulin |
| 02/12/2009 | US20090042796 Derivatives of the il-2 receptor gamma chain, their production and use |
| 02/12/2009 | US20090042788 Peptides and chemical compound for inhibition of SHP2 function |
| 02/12/2009 | US20090042199 Nucleotide sequences coding lymphocyte adhesion protein for use in treatment of autoimmunity, inflammation and infection |
| 02/12/2009 | US20090041849 Dissolution aids for oral peptide delivery comprising a biguanide |
| 02/12/2009 | US20090041833 Composition comprising gas-filled microcapsules for ultrasound mediated delivery |
| 02/12/2009 | US20090041830 Traumatic brain injury biomarker diagnostic |
| 02/12/2009 | US20090041825 Cell culture well-plates having inverted colloidal crystal scaffolds |
| 02/12/2009 | US20090041783 Anti-platelet membrane glycoprotein vi monoclonal antibody |
| 02/12/2009 | US20090041776 Production of cancer-specific antibodies in plants |
| 02/12/2009 | US20090041765 Modified immunoglobulins for use in prevention and treatment of autoimmune or inflammatory diseases |
| 02/12/2009 | US20090041742 Human dnase ii |
| 02/12/2009 | US20090041741 Modified enzyme and treatment method |
| 02/12/2009 | US20090041731 Treatment for Diabetes |
| 02/12/2009 | US20090041729 Process for Decellularizing Soft-Tissue Engineered Medical Implants, and Decellularized Soft-Tissue Medical Implants Produced |
| 02/12/2009 | US20090041725 Replication-Deficient RNA Viruses as Vaccines |
| 02/12/2009 | US20090041717 High affinity human antibodies to human nerve growth factor |
| 02/12/2009 | US20090041680 Wax Foamable Vehicle and Pharmaceutical Compositions Thereof |
| 02/12/2009 | CA2707292A1 Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue |
| 02/12/2009 | CA2695877A1 Novel .gamma.-secretase inhibitor |
| 02/12/2009 | CA2695844A1 Treatments and prevention of hydrocephalus |
| 02/12/2009 | CA2695405A1 N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases |
| 02/11/2009 | EP2022862A1 Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes |
| 02/11/2009 | EP2022853A1 Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof |
| 02/11/2009 | EP2022505A2 GLP-1, exendin-4, peptide analogs and uses thereof |
| 02/11/2009 | EP2021007A2 Patch for the treatment of the cellulite and localized adiposity |
| 02/11/2009 | EP2021001A2 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| 02/11/2009 | EP2020998A1 Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
| 02/11/2009 | EP2020991A2 A direct cellular energy delivery system |
| 02/11/2009 | EP1458747B1 Template-fixed peptidomimetics as inhibitors of serine proteases |
| 02/11/2009 | EP1370561B1 Tetrahydro-pyrazino[1,2-a]indoles for the treatment of central nervous disorders |
| 02/11/2009 | EP1317258B1 Use of allopurinol for the treatment of hypertension |
| 02/11/2009 | CN101365431A Novel use of nutraceutical compositions comprising resveratrol |
| 02/11/2009 | CN101362731A Heterocyclic compounds and methods of use |
| 02/11/2009 | CN101361972A Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| 02/11/2009 | CN101361881A Use of Chinese potato as protein medicine lysozyme intestinal-tract sorbefacient |
| 02/11/2009 | CN101361841A Use of traditional Chinese medicine in preparing medicine for treating diabetes cardiomyopathy |
| 02/11/2009 | CN101361748A Use of ginsenoside in preparing medicine for treating infrasound impariment |
| 02/11/2009 | CN101361727A Apoptosis inhibitor |
| 02/11/2009 | CN101361723A Improved pharmaceutical compositions |
| 02/11/2009 | CN101361718A Stable preparation method of decitabine freeze-dry preparation |
| 02/11/2009 | CN100459994C Pushi granule for treating abdominal distention after non-gastrointestinal surgery and preparation technology thereof |
| 02/10/2009 | US7488829 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 02/10/2009 | US7488822 Cyclocarbamate derivatives as progesterone receptor modulators |